AMBU® SURESIGHT™ CONNECT VIDEO LARYNGOSCOPE EXPANDS WITH PAEDIATRIC BLADE OPTIONS
Ambu has expanded its newly launched Ambu® SureSight™ Connect video laryngoscopy solution with the introduction of five new blades designed specifically for paediatric patients.
Today, Ambu announces the launch of additional sizes of video laryngoscope blades for the new Ambu® SureSight™ Connect video laryngoscopy solution.
Following the launch of the Ambu® SureSight™ Connect solution in February 2025, which included five blades of sizes traditionally used in adult patients, Ambu launches five additional blades aimed at paediatric patients. This increases the breadth of the Ambu® SureSight™ Connect offering to serve a wider patient group and ensure comprehensive care that meets the diverse needs of healthcare professionals and patients.
"With the introduction of the Ambu® SureSight™ Connect, I have all the tools I need to care for the broad range of complex patients I see as a paediatric anaesthesiologist – from our tiniest neonates to our largest teenagers."
CHRISTOPHER WARD, MD1
Department of Anesthesiology and Critical Care Medicine,
Children’s Hospital of Philadelphia, USA
A stronger airway visualization and pulmonology offering
In addition to the Ambu® SureSight™ Connect video laryngoscope, Ambu’s airway visualization and pulmonology offering includes the company’s range of single-use bronchoscopes, rhinolaryngoscopes, as well as single- and double-lumen tubes with an integrated camera for one-lung ventilation procedures2, in full integration with Ambu’s advanced digital software systems, Ambu® aView™ 2 Advance and Ambu® aBox™.
Ambu’s integrated airway visualization and pulmonology offering allows healthcare professionals to switch between solutions as needed. This aims to reduce task complexity, simplify workflow and improve efficiency, giving healthcare professionals more time to focus on patients, while maintaining high standards of patient safety.
Ambu will first engage in a controlled market release phase, collaborating with healthcare professionals at key hospitals in the USA and Great Britain to evaluate the new blades’ performance in clinical settings before engaging in a full launch later in 2025.
"With the addition of five new blades designed specifically for paediatric patients, we are significantly extending our Ambu® SureSight™ Connect solution to our customers. This important advancement allows us to meet their needs with the most comprehensive portfolio in the industry, ensuring they can work more efficiently to deliver the highest standards of patient care. Furthermore, it solidifies Ambu’s strong leadership position in airway management and pulmonology, showcasing our continued commitment to customer-centric innovation."
BRITT MEELBY JENSEN
Chief Executive Officer, Ambu
----------------------------------
1 Dr. Ward has not been compensated for his quote in this press release.
2 Ambu’s single-lumen tubes, Ambu® VivaSight™ 2 SLT, are not commercially available in the USA.
Keywords
Contacts
Anders HjortHead of Investor Relations
Tel:+45 2892 8881anhj@ambu.comTine Bjørn SchmidtDirector of Corporate Communications
Tel:+45 2264 0697tisc@ambu.comDocuments
About Ambu
Since 1937, Ambu’s DNA has been to rethink solutions together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 5,000 people in North America, Europe, Latin America and Asia Pacific.
For more information, please visit Ambu.com.
Subscribe to releases from Ambu A/S
Subscribe to all the latest releases from Ambu A/S by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Ambu A/S
AMBU APPOINTS NEW CHIEF MARKETING OFFICER1.5.2025 09:30:00 CEST | Press release
Jesper Johnsen Steen has been appointed as Ambu’s new Chief Marketing Officer, effective 1 May 2025.
AMBU EXPANDS CE MARK FOR EXISTING UROLOGY SOLUTION, ENABLES NEW TYPE OF PROCEDURE19.2.2025 10:41:31 CET | Press release
With the CE mark expansion for Ambu® aScope™ 5 Cysto HD, urologists will now be able to use the medical technology as a single-use flexible cysto-nephroscopy solution, reflecting Ambu’s commitment to addressing a growing range of urology needs for patients and healthcare professionals.
AMBU LAUNCHES NEW VIDEO LARYNGOSCOPY SOLUTION6.1.2025 16:05:55 CET | Press release
With the launch of the Ambu® SureSight™ Connect solution, Ambu offers clinicians the only airway visualisation and pulmonology offering that features a one-lung ventilation solution and includes all the devices recommended for intubation and airway assessment.
AMBU LAUNCHES HD CYSTOSCOPY SOLUTION IN THE U.S.17.10.2024 16:46:40 CEST | Press release
Following the FDA clearance for the Ambu® aScope™ 5 Cysto HD solution, Ambu introduces its HD cystoscope to urologists in the USA, expanding the urology offering and meeting advanced needs for cystoscopy procedures requiring superior image quality.
AMBU OBTAINS CE MARK FOR NEW GENERATION DUODENOSCOPY SOLUTION8.8.2024 13:00:00 CEST | Press release
Having obtained both CE mark and FDA clearance, Ambu continues its controlled market release phase, focused on evaluation in key hospitals in the USA and Europe.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom